Cytochrome P450BM-3 and P450 11A1 retain Compound I (FeO3+) chemistry with electrophilic substrates poised for Compound 0 (Fe3+O2−) reactions
Journal of Biological Chemistry · 2025-07 · 301 (7) · 110378
DOI: 10.1016/j.jbc.2025.110378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025-07. Verfasst von Kevin D McCarty und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 Enzyme System, Bacterial Proteins, NADPH-Ferrihemoprotein Reductase, Ferric Compounds. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institutes of Health, National Science Foundation.
Abstract (Originalsprache)
The catalytic cycle of cytochrome P450 (P450) enzymes involves ferric peroxide anion (Fe3+O2-, Compound 0) and perferryl oxygen (FeO3+, Compound I) intermediates. Compound I is generally viewed as responsible for most P450-catalyzed oxidations, but Compound 0 has been implicated in the oxidation of some carbonyl compounds, particularly deformylation reactions. We considered the hypothesis that Compound 0 could also attack other electrophilic carbon atoms and accordingly positioned keto groups at preferred hydroxylation sites of substrates for two P450s with well-defined catalytic reactions, bacterial P450BM-3 (102A1), and human P450 11A1. The predicted products of Compound I and Compound 0 reactions were analyzed. With the normally preferred ω-1 site blocked, P450BM-3 oxidized 12-oxotridecanoic acid (12-oxo C13:0) only at the ω-2 position (yielding 11-hydroxy,12-oxotridecanoic acid), indicative of a Compound I oxidation. P450 11A1 is highly selective for catalyzing the 22R-hydroxylation of cholesterol (and some other sterols) in the first step of its overall side-chain cleavage reaction. With 22-oxocholesterol as the substrate, P450 11A1 (slowly) generated only 23-hydroxy,22-oxocholesterol, indicative of Compound I oxidation. Neither P450 generated the products expected from nucleophilic Compound 0 reactions. We conclude that the strategic placement of electrophilic oxo substituents at sites of substrate hydroxylation failed to divert the oxidation mechanism to a Compound 0 pathway with either enzyme. Instead, the Compound I mechanism-blocked at the preferred reaction site-was redirected to neighboring carbons, suggesting that the basis for Compound 0-mediated reactions lies in chemical properties of the enzyme rather than those of the substrate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
- Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. Electronic address: f.guengerich@vanderbilt.edu.
Förderung
- NIGMS NIH HHS
- National Institutes of Health
- National Science Foundation
- Foundation for the National Institutes of Health
Zitieren
APA
McCarty, K. D., Tateishi, Y., & Guengerich, F. P. (2025). Cytochrome P450BM-3 and P450 11A1 retain Compound I (FeO3+) chemistry with electrophilic substrates poised for Compound 0 (Fe3+O2−) reactions. Journal of Biological Chemistry, 301(7), 110378. https://doi.org/10.1016/j.jbc.2025.110378
Vancouver
McCarty KD, Tateishi Y, Guengerich FP. Cytochrome P450BM-3 and P450 11A1 retain Compound I (FeO3+) chemistry with electrophilic substrates poised for Compound 0 (Fe3+O2−) reactions. Journal of Biological Chemistry. 2025;301(7):110378. doi:10.1016/j.jbc.2025.110378
BibTeX
@article{McCarty2025,
author = {McCarty, Kevin D and Tateishi, Yasuhiro and Guengerich, F Peter},
title = {Cytochrome P450BM-3 and P450 11A1 retain Compound I (FeO3+) chemistry with electrophilic substrates poised for Compound 0 (Fe3+O2−) reactions},
journal = {Journal of Biological Chemistry},
year = {2025},
volume = {301},
number = {7},
pages = {110378},
doi = {10.1016/j.jbc.2025.110378}
}
EUVIMED